6-13-2022The Ending the HIV Epidemic in the U.S. (EHE) initiative set a goal to virtually eliminate new HIV infections in the U.S. by 2030. This ambitious and unpreceden…
6-2-2022Cross-posted from NIAID NewsroomStrategy May Offer Alternative to Daily AntiretroviralsIndividuals with HIV who began taking antiretroviral therapy (ART) in the…
3-23-2022Cross-posted from NIAID NewsroomPhase 1 Study Is Among First to Examine mRNA Technology for HIVThe National Institute of Allergy and Infectious Diseases (NIAID)…
3-1-2022As the 2022 virtual Conference on Retroviruses and Opportunistic Infections (CROI 2022) came to a close, NIH’s Dr. Carl Dieffenbach joined HIV.gov for a video…
2-17-2022In an HIV.gov video conversation yesterday, NIH’s Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the 2022 vir…
2-15-2022Cross-posted from NIAID NewsroomWoman Has Remained Without Detectable HIV for 14 MonthsA woman with HIV who received a cord blood stem cell transplant to treat …
2-9-2022Next week, for the 11th year in a row, HIV.gov will begin sharing updates on the latest HIV research from the 2022 virtual Conference on Retroviruses and Opport…
12-21-2021Cross-posted from NIAID NewsroomApproval Marks Pivotal Expansion of HIV Prevention Options in the United StatesYesterday the U.S. Food and Drug Administration a…
12-15-2021Cross-posted from the NIAID NewsroomNIAID Scientists Developed Vaccine PlatformAn experimental HIV vaccine based on mRNA—the same platform technology used in …
11-30-2021NIH-Funded Study Estimates Global Progress Toward UNAIDS GoalCross-posted from NIAID NewsroomAmong people with HIV worldwide who are receiving antiretroviral th…
